Can someone please put this in layman's terms from a research report into CTR released this morning?
Risks associated with this project include CTR failing to secure necessary funding and we feel it appropriate
to ascribe a raft of conservative criteria, including a 50% commercial risk factor, to our valuation at this stage.
As such, we ascribe a preliminary valuation of 0.15p per share (fully diluted).
is the report suggesting 15c per share?
PS. Plenty of fanfare over at NWE over the SP rising today, so maybe watch that as well.
- Forums
- ASX - Day Trading
- daytrading feb 14 morning
daytrading feb 14 morning, page-8
Featured News
Featured News
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online